Biotechnology
New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC inAustralia in more than 20 years * * ZEPZELCA approval granted under a provisional regulatory pathway * US FDA and TGA collaborated via 'Project Orbis' to accelerate avail...
2021-09-14 18:57
1525
PharmAbcine to Participate in ACCESS CHINA Biotech Forum
DAEJEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESSCHINA Biotech Forum. The event will...
2021-09-13 20:00
1244
Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
INCHEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part...
2021-09-13 12:41
1497
PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer
DAEJEON, South Korea, Sept. 9, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT) application for the combination therapy of...
2021-09-09 20:00
1634
China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up
HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...
2021-09-09 18:06
1842
Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility
SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...
2021-09-09 11:40
3493
The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare
Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...
2021-09-08 19:00
3760
Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability
PALO ALTO, Calif., Sept. 7, 2021 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe , https://ipeace.com/), aPalo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinica...
2021-09-08 02:00
1500
Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant
SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...
2021-09-06 13:44
3772
GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates
SUZHOU, China, Sept. 5, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1...
2021-09-06 09:00
1429
AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases
BEIJING, Sept. 5, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, announced during the recent "China International Trade in Servi...
2021-09-06 08:00
1294
WuXi AppTec Receives AA ESG Rating from MSCI
SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...
2021-09-06 08:00
2517
PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC
DAEJEON, South Korea, Sept. 3, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II c...
2021-09-03 20:00
1847
Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment
SHANGHAI, Sept. 2, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, today announced the clearance of the Investigational New Drug (IND) application for Phase III study of ARVN003 (pilocarpine microdose o...
2021-09-03 08:00
1668
Clinical trial provides preliminary evidence of a cure for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and Long Covid
BURLINGAME, Calif., Sept. 3, 2021 /PRNewswire/ -- Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS. The company intends to test CT38 in Long Covid, the post-acut...
2021-09-03 06:00
1921
I-Mab Added to FTSE Russell Global Equity Index Series
SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Eq...
2021-09-02 20:00
5768
ETERN Therapeutics Announces Completion of Series B Financing to Advance the Protein Liquid-Liquid Phase Separation Technology Platform and Accelerate the Development of Novel Drugs to Target "Undruggable" Proteins
SHANGHAI, Aug. 31, 2021 /PRNewswire/ -- ETERN Therapeutics, a clinical-stage biotech company focusing on developing novel technologies to target "undruggable" proteins, today announced the completion of a Series B financing round. The financing was co-led by GL Ventures and AstraZeneca-CICC Healt...
2021-09-01 10:00
1576
Deebio's Global Bio-enzyme Journey: 27 Years, 30 Countries and Regions
DEYANG, China, Aug. 31, 2021 /PRNewswire/ -- Sichuan Deebiotech Co., Ltd. (hereinafter referred to as Deebio) recently celebrated its 20th anniversary of continuous exports to the EU during the 86th API China. The company's European partners sent congratulatory video, while domestic partners atte...
2021-08-31 19:46
926
Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed
TAIPEI and SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its oral new drug, Silmitasertib, had received a positive feedbac...
2021-08-31 19:00
1564
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...
2021-08-31 18:00
3397
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5209
